Regeneron (REGN) Tops Q2 EPS by 75c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Pharma (REGN) PT Raised to $305 at Barclays
August 3, 2018 5:10 AM EDTBarclays raised its price target on Regeneron Pharma (NASDAQ: REGN) to $305.00 (from $290.00) while maintaining a Underweight rating.
... MoreRegeneron Pharma (REGN) PT Raised to $385 at Cowen
August 2, 2018 3:51 PM EDTCowen raised its price target on Regeneron Pharma (NASDAQ: REGN) to $385.00 (from $350.00) while maintaining a Market Perform rating.
Analyst Phil Nadeau commented, "REGN reported Q2:18 Eylea sales of $992MM, (+0.8% Q/Q, +8% Y/Y) just below the consensus $1BE. Solid performance from other key... More
Regeneron Pharma (REGN) PT Raised to $440 at Oppenheimer on Q2 Report; 'Eylea Static Decreasing, 2H18 Product Launches'
August 2, 2018 3:27 PM EDTOppenheimer raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $410.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Hartaj Singh notes a positive outlook on the shares, as REGN reported second quarter earnings per share and sales... More
Regeneron Pharma (REGN) PT Raised to $440 at Evercore ISI
August 2, 2018 11:48 AM EDTEvercore ISI raised its price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $405.00) while maintaining a Outperform rating.
Analyst Josh Schimer noted strong performance across the board for product revenue and expenses. Dupixent/OUS Eylea were strongest spots.
... More